Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency

Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency

Last updated: November 2026

Key points in 60 seconds

  • GLP-1 receptor agonists (semaglutide, liraglutide) and tirzepatide are now widely used for diabetes and obesity, so eye clinics see many patients taking them.
  • Rapid falls in HbA1c can cause early worsening of diabetic retinopathy; examine the retina before starting and follow closely in the first year if retinopathy is present.
  • Semaglutide has been linked to NAION; the European Medicines Agency lists it as a very rare side effect.
  • In idiopathic intracranial hypertension, weight loss is disease-modifying; bariatric surgery and GLP-1 drugs both have trial evidence.
  • After bariatric surgery, look for vitamin A deficiency (night blindness, xerophthalmia), and also B1, B12 and copper deficiency causing ocular motor or optic nerve problems.

"I have started weekly injections for weight loss. Will they affect my eyes?" Eye doctors now hear this every week. The answer depends on the patient: a person with diabetic retinopathy, a young woman with papilloedema, a man with a crowded disc, and a patient years after gastric bypass each face a different eye issue.

The medicines in brief

MedicineTypeEye points
Semaglutide (weekly injection, also oral)GLP-1 receptor agonistEarly worsening of diabetic retinopathy; NAION signal
Liraglutide, dulaglutide, exenatideGLP-1 receptor agonistsClass effects on glucose; exenatide studied in IIH
TirzepatideDual GIP and GLP-1 receptor agonistLarge weight loss; retinal data still accumulating
Newer agents (oral small-molecule GLP-1 agonists such as orforglipron; triple agonists such as retatrutide; amylin combinations)In late trials or recently approvedEye safety data still limited
Phentermine-topiramateAppetite suppressant plus anticonvulsantTopiramate: acute bilateral angle closure and myopic shift; phentermine: mydriasis
OrlistatLipase inhibitorMalabsorption of fat-soluble vitamins, including vitamin A
MetforminBiguanideLong-term use can lower vitamin B12

Diabetic retinopathy: early worsening

In the SUSTAIN-6 trial, semaglutide was associated with more retinopathy complications than placebo, mostly in patients who already had retinopathy and whose HbA1c fell quickly. The same "early worsening" was seen decades ago with intensive insulin therapy in the DCCT and is thought to reflect the speed of glucose lowering rather than a direct toxic effect. Long-term, better glucose control protects the retina. The FOCUS trial is studying the effect of semaglutide on retinopathy directly.

Practical approach

  1. Ask every diabetic patient about GLP-1 or tirzepatide treatment, and when it started.
  2. Examine the retina (with OCT if possible) before or soon after starting, especially if HbA1c is high or retinopathy is known.
  3. If there is moderate or worse non-proliferative retinopathy, proliferative retinopathy or macular oedema, review every 3 to 4 months in the first year.
  4. Treat sight-threatening disease as usual. Do not ask the physician to stop the drug without good reason; discuss a slower reduction in HbA1c if retinopathy is advanced.
  5. Expect temporary changes in refraction while glucose is changing; delay new spectacles until it is stable.

NAION

Observational studies since 2024 have reported a higher rate of non-arteritic anterior ischaemic optic neuropathy in people taking semaglutide, and in 2025 the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide medicines (up to 1 in 10,000 people). Patients with a crowded disc, sleep apnoea or previous NAION in one eye may deserve a discussion with their physician. The details are in semaglutide and NAION.

Idiopathic intracranial hypertension

  • Weight gain is a major risk factor, and weight loss of around 5 to 15% often brings remission.
  • The IIH:WT trial showed that bariatric surgery lowered intracranial pressure more than a community weight-management programme, with the effect lasting at two years.
  • GLP-1 receptor agonists reduce CSF secretion in laboratory studies; exenatide lowered ICP in a small trial, and observational studies of semaglutide and tirzepatide in IIH are encouraging.
  • Weight loss is a long-term plan. It does not replace urgent treatment (acetazolamide, CSF shunting or optic nerve sheath fenestration) when vision is threatened.

After bariatric surgery

DeficiencyEye findingsWhen
Vitamin ANight blindness, conjunctival and corneal xerosis, Bitot spots, keratomalacia; abnormal ERG; fundus flecksMonths to many years after malabsorptive operations (biliopancreatic diversion, Roux-en-Y gastric bypass), especially with poor follow-up
Thiamine (vitamin B1)Wernicke encephalopathy: nystagmus, ophthalmoplegia, ataxia, confusionOften in the first months, especially with persistent vomiting
Vitamin B12Bilateral optic neuropathy with central or centrocaecal scotomasYears after surgery without supplements
CopperOptic neuropathy, myeloneuropathyMonths to years; also with high zinc supplements
Vitamin EOphthalmoplegia, pigmentary retinopathy (rare)Long-term malabsorption

Night blindness or dry, gritty eyes after bariatric surgery is vitamin A deficiency until proved otherwise. Check serum retinol, start replacement with the physician, and look for corneal involvement. Untreated xerophthalmia can progress to corneal melt.

Other practical points

  • Anaesthesia: GLP-1 drugs slow gastric emptying and may increase aspiration risk under general anaesthesia or sedation. Follow your anaesthesia department's current policy; most cataract surgery under topical or local anaesthesia is unaffected.
  • Refraction: fluctuating glucose with rapid weight loss changes the refraction; avoid prescribing until stable.
  • Topiramate: any patient on a weight-loss combination containing topiramate who develops sudden bilateral blur, myopia or eye pain needs an urgent angle assessment.

Pearls

  • Ask about weight-loss injections in every diabetic and every patient with a swollen or crowded disc.
  • Rapid HbA1c reduction plus existing retinopathy: follow closely in the first year.
  • Weight loss is disease-modifying in IIH; refer to weight-management services early.
  • Night blindness after gastric bypass: think vitamin A.
  • Sudden bilateral myopia and angle closure on a weight-loss pill: think topiramate.

Common mistakes

  • Advising patients to stop GLP-1 drugs because of early retinopathy worsening without discussing it with the physician.
  • Prescribing new spectacles during rapid changes in glucose.
  • Missing vitamin A deficiency because surgery was "many years ago".
  • Relying on weight loss alone when IIH is threatening vision.

Test yourself: flip cards

Quick quiz

Related: Semaglutide and NAION: What the Evidence Says, Diabetic Retinopathy: Classification and Management for Residents, Papilloedema vs Pseudopapilloedema, Fenofibrate, GLP-1 Agonists and Diabetic Retinopathy: What Residents Should Know, Optic Neuritis vs NAION vs Arteritic AION: How to Tell Them Apart.

Key sources

  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844
  • Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142:732-739
  • European Medicines Agency, PRAC. Semaglutide medicines: very rare risk of NAION. June 2025
  • Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021;78:678-686
  • Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146:1821-1830
  • Lee WB, Hamilton SM, Harris JP, Schwab IR. Ocular complications of hypovitaminosis A after bariatric surgery. Ophthalmology. 2005;112:1031-1034

📘 Want more exam-ready material? See Most Commons in Ophthalmology on Kindle, or browse all my books.

How to cite this page

Patel D. Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency. RPC Rounds (Sadbhaav Eye Clinic). Updated November 2026. Available at: https://www.sadbhaavclinic.com/weight-loss-drugs-bariatric-surgery-eye.html. Accessed [date].

Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy

Consultant, Cataract & Refractive Surgery — among a small number of AIIMS-trained ophthalmologists practicing in Gujarat. Read full credentials & experience or view his 28 publications on ResearchGate.

📚 Also the author of OKAT Decoded, FRCOphth Decoded and other high-yield ophthalmology exam-prep books used by residents and PG aspirants.

Looking for an eye specialist in Ahmedabad? Diabetic eye care at Sadbhaav or book a consultation with Dr. Dhaval Patel.